Literature DB >> 19358520

CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells.

Sivan Zeno1, Menashe Zaaroor, Svetlana Leschiner, Leo Veenman, Moshe Gavish.   

Abstract

The 18 kDa translocator protein (TSPO), formerly known as the peripheral-type benzodiazepine receptor, has been reported to be closely associated with the mitochondrial permeability transition pore (MPTP). TSPO is believed to exert pro-apoptotic functions via modulation of MPTP opening. Cobalt chloride (CoCl(2)), which is sometimes used as a hypoxia mimicking agent, is also known to be able to induce apoptosis. One of our questions was whether CoCl(2) may induce apoptosis via the TSPO. To address this question, we used the U118MG human glioblastoma cell line. We applied the specific TSPO ligand, PK 11195, as well as TSPO knockdown with siRNA and studied their influence on the effects of CoCl(2) on cell death, including activation of the mitochondrial apoptosis pathway. To assay TSPO expression, we applied binding assays and Western blotting to whole cell homogenates and mitochondrial fractions. To assay activation of the mitochondrial apoptosis pathway, including some of the cellular mechanisms involved, we determined the incidence of collapse of the mitochondrial membrane potential (Deltapsi(m)) and cardiolipin oxidation and measured the level of DNA fragmentation to assay apoptotic rates. We found that the TSPO ligand, PK 11195, significantly counteracted induction of cell death by 0.4 mM CoCl(2), including apoptosis, collapse of the Deltapsi(m), and cardiolipin oxidation. Moreover, we found that TSPO knockdown with siRNA fully protected against mentioned cell death mechanisms. Thus, we found that the TSPO is required for cell death induction by CoCl(2), including apoptosis. In conclusion, our studies show that activation of TSPO by CoCl(2) application is required for ROS generation, leading to cardiolipin oxidation, and collapse of the Deltapsi(m), as induced by CoCl(2).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358520     DOI: 10.1021/bi900064t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  26 in total

1.  In vitro mitochondrial effects of PK 11195, a synthetic translocator protein 18 kDa (TSPO) ligand, in human osteoblast-like cells.

Authors:  Nahum Rosenberg; Orit Rosenberg; Abraham Weizman; Svetlana Leschiner; Yaakov Sakoury; Fuad Fares; Michael Soudry; Gary Weisinger; Leo Veenman; Moshe Gavish
Journal:  J Bioenerg Biomembr       Date:  2011-11-30       Impact factor: 2.945

2.  The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; Andrew Bauer; Aneeta Patel; John Costello; Kenneth D Burman; Leonard Wartofsky; Matthew J Hardwick; Vasyl V Vasko
Journal:  J Endocrinol       Date:  2012-05-29       Impact factor: 4.286

3.  CRISPR/Cas9‒Mediated Tspo Gene Mutations Lead to Reduced Mitochondrial Membrane Potential and Steroid Formation in MA-10 Mouse Tumor Leydig Cells.

Authors:  Jinjiang Fan; Kevin Wang; Barry Zirkin; Vassilios Papadopoulos
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

4.  Pomegranate juice and punicalagin attenuate oxidative stress and apoptosis in human placenta and in human placental trophoblasts.

Authors:  Baosheng Chen; Methodius G Tuuli; Mark S Longtine; Joong Sik Shin; Russell Lawrence; Terrie Inder; D Michael Nelson
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-28       Impact factor: 4.310

5.  Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state.

Authors:  Judy Choi; Masataka Ifuku; Mami Noda; Tomás R Guilarte
Journal:  Glia       Date:  2011-02       Impact factor: 7.452

Review 6.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

7.  TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control.

Authors:  Jemma Gatliff; Daniel East; James Crosby; Rosella Abeti; Robert Harvey; William Craigen; Peter Parker; Michelangelo Campanella
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

8.  In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein.

Authors:  Nahum Rosenberg; Orit Rosenberg; Abraham Weizman; Leo Veenman; Moshe Gavish
Journal:  J Bioenerg Biomembr       Date:  2013-03-09       Impact factor: 2.945

Review 9.  Recent progress in the use of mitochondrial membrane permeability transition pore in mitochondrial dysfunction-related disease therapies.

Authors:  Yuting Cui; Mingyue Pan; Jing Ma; Xinhua Song; Weiling Cao; Peng Zhang
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

10.  The TSPO Ligands MGV-1 and 2-Cl-MGV-1 Differentially Inhibit the Cigarette Smoke-Induced Cytotoxicity to H1299 Lung Cancer Cells.

Authors:  Nidal Zeineh; Rafael M Nagler; Martin Gabay; Fadi Obeid; Meygal Kahana; Abraham Weizman; Moshe Gavish
Journal:  Biology (Basel)       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.